Treatment With Rituxan May Reduce Recurrence of Follicular Lymphoma (HealthDay)
HealthDay – THURSDAY, May 20 (HealthDay News) — The final phase of a drug
study finds that two years of treatment with rituximab (Rituxan) cuts in
half the risk that follicular lymphoma patients who respond to
chemotherapy will suffer a recurrence of the disease.